Taysha director granted RSUs and stock options

Taysha Gene Therapies director John A. Stalfort III reported equity awards in the company’s common stock.

Rhea-AI Filing Summary

Taysha Gene Therapies director John A. Stalfort III reported equity awards in the company’s common stock. He received 21,335 shares through a restricted stock unit award at a price of $0.00 per share. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to his continued service as a director.

He was also granted stock options for 42,671 shares of common stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, he holds 1,176,559 shares of common stock directly and 884,290 shares indirectly through the John A. Stalfort III 2018 Irrevocable Trust.

Insights

Equity compensation analyst

Routine director equity grants with modest scale and standard vesting.

Director John A. Stalfort III received 21,335 restricted stock units and options for 42,671 shares at an exercise price of $5.97 per share. Both are compensation-related awards, not open-market purchases or sales, and therefore carry limited signaling value for the company’s outlook.

The RSUs and options vest on the earlier of the next annual stockholders meeting or June 1, 2027, contingent on continued board service. After these grants, he reports 1,176,559 shares held directly and 884,290 shares held indirectly through a 2018 irrevocable trust. These figures indicate a substantial ongoing equity stake, framing the awards as part of normal director compensation rather than a change in strategic positioning.

Insider Trade Summary

Grant/Award: 64,006 shares

Grant/Award 3 txns

Insider Stalfort John A III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,671	$0.00	$0.00
Grant/Award	Common Stock	21,335	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 42,671 contracts (Direct); Common Stock — 1,176,559 shares (Direct); Common Stock — 884,290 shares (Indirect, See footnote)

Footnotes (3)

1. F1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
2. F2. The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.
3. F3. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Key Figures

RSU award size: 21,335 shares Option grant size: 42,671 shares Option exercise price: $5.97 per share +4 more

7 metrics

RSU award size 21,335 shares Restricted stock unit award vesting by June 1, 2027 or next annual meeting

Option grant size 42,671 shares Stock options on common stock granted to director

Option exercise price $5.97 per share Exercise price for 42,671 stock options

Option expiration June 1, 2036 Expiration date for new stock options

Direct holdings after awards 1,176,559 shares Common stock held directly by John A. Stalfort III after transactions

Indirect trust holdings 884,290 shares Common stock held by 2018 irrevocable trust associated with reporting person

RSU grant price $0.00 per share Grant price for 21,335 RSUs awarded to director

Key Terms

restricted stock unit ("RSU") award, Stock Option (right to buy), Irrevocable Trust, annual stockholders meeting, +1 more

5 terms

restricted stock unit ("RSU") award financial

"Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027..."

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 5.9700 per share..."

Irrevocable Trust financial

"The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust..."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

annual stockholders meeting financial

"The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting..."

exercise price financial

"Stock Option (right to buy) with an exercise price of 5.9700..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Taysha (TSHA) director John A. Stalfort III receive?

He received 21,335 restricted stock units and stock options for 42,671 shares of Taysha common stock. Both awards were granted at $0.00 per share, with the options carrying a $5.97 exercise price and a long-dated expiration in 2036.

When do the new Taysha (TSHA) RSUs and options for John A. Stalfort III vest?

The RSUs and underlying shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting. Vesting is conditioned on John A. Stalfort III’s continued service as a director through the applicable vesting date under the award terms.

What is the exercise price and expiration for the new Taysha (TSHA) stock options?

The stock options granted to John A. Stalfort III cover 42,671 shares at an exercise price of $5.97 per share. These options are scheduled to expire on June 1, 2036, giving a long time window for potential exercise if vesting conditions are met.

How many Taysha (TSHA) shares does John A. Stalfort III hold after these transactions?

After the reported awards, he holds 1,176,559 shares of Taysha common stock directly. In addition, 884,290 shares are held indirectly through the John A. Stalfort III 2018 Irrevocable Trust, where securities are held by trustee Gineane Holly Stalfort.

Were the recent Taysha (TSHA) insider filings open-market buys or routine grants?

The reported transactions are routine compensation-related grants, not open-market trades. They include a restricted stock unit award and a stock option grant, both recorded with transaction code “A,” which denotes grant, award, or other acquisition under SEC Form 4 reporting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stalfort John A III

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, SUITE 1430

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		21,335(1)	A	$0	1,176,559	D
Common Stock								884,290	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.97	06/01/2026		A		42,671		(3)	06/01/2036	Common Stock	42,671	$0	42,671	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

2. The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.

3. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

	/s/ Kamran Alam, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)